Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review
Wound Repair and Regeneration · 2025-09 · 33 (5)
DOI: 10.1111/wrr.70085 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Wound Repair and Regeneration, 2025-09. Verfasst von Fiona S Gruzmark und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Diabetic Foot, Wound Healing, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptide 1. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Globally, there are 537 million people with diabetes, with an estimated 19%–344% of these people developing a diabetic foot ulcer, and 10% dying within a year of being diagnosed with a diabetic foot ulcer. Risk factors for developing a diabetic foot ulcer include age, sex, ethnicity, chronically elevated HbA 1c , smoking history, cardiovascular disease, end‐stage renal disease, and retinopathy. Diabetic foot ulcer recurrence rates are as high as 20%, and they have vast complications, including lower‐extremity amputations. More recently, there has been a surge in the use of glucagon‐like peptide 1 receptor agonists in managing diabetes and weight loss. The use of glucagon‐like peptide 1 receptor agonists in treating diabetic foot ulcers in humans has not been extensively studied, but there are reports of using glucagon‐like peptide 1 receptor agonists in other dermatologic diseases with positive outcomes, including androgenetic alopecia and hidradenitis suppurativa. This review aims to explore the potential of using systemic glucagon‐like peptide 1 receptor agonists in managing diabetic foot ulcers, describing their effects on modulating wound repair, microvascular function, neuropathic symptoms, apoptosis, weight loss, oxidative stress, and inflammation. Additionally, a systematic review, following PRISMA guidelines, was conducted assessing the rate of diabetic foot complications in patients using glucagon‐like peptide 1 receptor agonists when compared to a control group, with the results suggesting their potentially protective role. By managing multiple facets of diabetic foot ulcer pathophysiology, the use of glucagon‐like peptide 1 receptor agonists may aid in their management and thus prevent recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
ORCID-Profile: Fiona S Gruzmark, Gabriela E Beraja
Zitieren
APA
Gruzmark, F. S., Beraja, G. E., Jozic, I., & Lev-Tov, H. A. (2025). Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review. Wound Repair and Regeneration, 33(5). https://doi.org/10.1111/wrr.70085
Vancouver
Gruzmark FS, Beraja GE, Jozic I, Lev-Tov HA. Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review. Wound Repair and Regeneration. 2025;33(5). doi:10.1111/wrr.70085
BibTeX
@article{Gruzmark2025,
author = {Gruzmark, Fiona S and Beraja, Gabriela E and Jozic, Ivan and Lev-Tov, Hadar A},
title = {Exploring the Role of GLP ‐1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review},
journal = {Wound Repair and Regeneration},
year = {2025},
volume = {33},
number = {5},
doi = {10.1111/wrr.70085}
}
EUVIMED